My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Tenofovir Gel Cost

Tenofovir Gel Cost


Published in BMJ Infectious Diseases, this article reports on a modeling study that used the results of the CAPRISA 004 trial of tenofovir gel to estimate the population-level impact of the gel on HIV and HSV-2 transmission and the price thresholds at which widespread product introduction would be as cost-effective as male circumcision for HIV prevention in urban South Africa.

There is urgent need for effective HIV prevention methods that women can initiate. The CAPRISA 004 trial showed that a tenofovir-based vaginal microbicide had significant impact on HIV incidence among women. This study uses the trial findings to estimate the population-level impact of the gel on HIV and HSV-2 transmission, and price thresholds at which widespread product introduction would be as cost-effective as male circumcision in urban South Africa.

Information about drug Tenofovir includes cost of the drug and the type of drug - tablet, capsule, syrup, cream, gel, ointment, liquid or injection. To view the price of the drug, click on the brand name. The generic Tenofovir is manufactured by 6 companies. Medindia's drug directory has currently 6 Brands of Tenofovir listed. New generics and brands are constantly being updated as and when they are approved by drug controller and available in the pharmacies.

Before you buy Tenofovir Disoproxil Fumarate 300 mg, compare the lowest cost Tenofovir Disoproxil Fumarate prices from PharmacyChecker-verified online pharmacies below. The price range for Tenofovir Disoproxil Fumarate 300 mg is $1.28 - $3.97 per pill or unit.

HSV-2 is the strain of the herpes simplex virus that causes most cases of genital herpes. It's a common infection: In the United States, an estimated 16 percent of 14- to 49-year-olds have an HSV-2 infection, according to the U.S. Centers for Disease Control and Prevention.

The virus is even more common in some other parts of the world. In sub-Saharan Africa, up to 80 percent of sexually active women and half of sexually active men are infected. The new study took place in South Africa, one of those hardest-hit countries.

The gel, which contains a drug called tenofovir, is still experimental, stressed study leader Dr. Salim Abdool Karim, director of the Center for the AIDS Program of Research, in Durban, South Africa.

Further research will probably be necessary for drug regulators in various countries to consider approving the medication, Karim said.

The current trial was not primarily designed to test tenofovir gel against HSV-2; its main aim was to curb the risk of HIV transmission. The oral formulation of tenofovir, which is marketed as Viread, is already used to treat HIV, the virus that causes AIDS.

Earlier results from the trial had suggested the gel version can reduce women's risk of contracting HIV. However, follow-up research yielded disappointing results -- largely because many women were not able to use the gel consistently.

With any such preventive therapy, "how people use it is important," said Dr. Connie Celum, a spokeswoman for Infectious Diseases Society of America and a professor at the University of Washington, in Seattle.

Still, she called the gel a "promising intervention that could reduce herpes acquisition."

Celum, who was not involved in the research, has studied oral tenofovir as a way to prevent herpes simplex virus type 2 infection. In a trial reported last year, her team found that the medication had a modest benefit among the African adults they studied.

The gel formulation, Celum said, contains much higher concentrations of the drug than the tablet form.

HSV-2 infection itself is not usually dangerous. It sometimes causes painful sores around the genitals, rectum or mouth. More often, though, it causes no symptoms or only mild ones -- which means most people with the infection are unaware of it.

However, in rare cases, the virus invades the brain and triggers potentially deadly inflammation. And if it's passed from mother to newborn, HSV-2 can be fatal for the baby.

What's more, Celum said, genital herpes can double the risk of becoming infected with HIV -- which is especially troubling in areas of the world where both infections are prevalent.

"We don't have a cure for HSV-2, and we don't have a vaccine," Celum pointed out.

Once a person is infected, the virus hides out in nerve cells and reactivates periodically, sometimes causing symptoms. In wealthier countries, there are a few medications that can treat symptoms and, if taken daily, help suppress new outbreaks. They include acyclovir (Zovirax), famciclovir (Famvir) and valacyclovir (Valtrex).

Daily treatment with those drugs can also reduce the chances of passing herpes simplex virus type 2 to a sexual partner, but it doesn't eliminate the risk.

Both Celum and Karim said tenofovir gel could offer an additional weapon against HSV-2 not only in developing countries, but wealthier ones, too.

The current study looked at a subgroup of women who'd taken part in the larger trial testing tenofovir gel against HIV. The group included 422 who were free of HSV-2 when they were randomly assigned to use either the drug or an inactive placebo gel; they were told to apply it vaginally before and after having sex.

Over 18 months, women who used the drug-containing gel were 51 percent less likely to contract HSV-2, compared to the placebo group, the investigators found.

Condoms, when used consistently, can also lower HSV-2 risk. But worldwide, many women have a difficult time "negotiating" condom use with their partners, Karim pointed out.

The gel could give them an option they can better control, he said.

One looming question is what the cost would be.

The cost was about $2 per applicator, Karim said. "For the product to be viable," he added, "it will have to cost only a few cents."

Know More About This Medicine and Buy Now :